6-136822785-C-G
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000288.4(PEX7):āc.120C>Gā(p.Tyr40Ter) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000097 in 1,349,960 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (ā ā ). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000288.4 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PEX7 | NM_000288.4 | c.120C>G | p.Tyr40Ter | stop_gained | 1/10 | ENST00000318471.5 | NP_000279.1 | |
PEX7 | XM_006715502.3 | c.120C>G | p.Tyr40Ter | stop_gained | 1/7 | XP_006715565.1 | ||
PEX7 | XM_047418874.1 | c.120C>G | p.Tyr40Ter | stop_gained | 1/6 | XP_047274830.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PEX7 | ENST00000318471.5 | c.120C>G | p.Tyr40Ter | stop_gained | 1/10 | 1 | NM_000288.4 | ENSP00000315680 | P1 | |
PEX7 | ENST00000367756.8 | c.120C>G | p.Tyr40Ter | stop_gained | 1/4 | 3 | ENSP00000356730 | |||
PEX7 | ENST00000541292.6 | c.120C>G | p.Tyr40Ter | stop_gained, NMD_transcript_variant | 1/11 | 5 | ENSP00000441004 | |||
PEX7 | ENST00000678593.1 | c.120C>G | p.Tyr40Ter | stop_gained, NMD_transcript_variant | 1/8 | ENSP00000503841 |
Frequencies
GnomAD3 genomes AF: 0.0000593 AC: 9AN: 151898Hom.: 0 Cov.: 35
GnomAD3 exomes AF: 0.0000833 AC: 2AN: 24010Hom.: 0 AF XY: 0.0000655 AC XY: 1AN XY: 15258
GnomAD4 exome AF: 0.000102 AC: 122AN: 1198062Hom.: 0 Cov.: 32 AF XY: 0.000106 AC XY: 62AN XY: 583098
GnomAD4 genome AF: 0.0000593 AC: 9AN: 151898Hom.: 0 Cov.: 35 AF XY: 0.0000539 AC XY: 4AN XY: 74206
ClinVar
Submissions by phenotype
Rhizomelic chondrodysplasia punctata type 1 Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Aug 08, 2017 | Variant summary: The PEX7 c.120C>G (p.Tyr40X) variant results in a premature termination codon, predicted to cause a truncated or absent PEX7 protein due to nonsense mediated decay, which are commonly known mechanisms for disease. This variant is absent in 5288 control chromosomes (indicated to be a low-quality site in ExAC). Multiple publications have cited the variant in affected individuals dx with RCDP1, however, it has been noted to also be found in Refsum Disease pts (van der Brink_2003). In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as "likely pathogenic/pathogenic." Taken together, this variant is classified as pathogenic. - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Feb 01, 2003 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | May 22, 2014 | - - |
Peroxisome biogenesis disorder 9B Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 25, 2023 | This sequence change creates a premature translational stop signal (p.Tyr40*) in the PEX7 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in PEX7 are known to be pathogenic (PMID: 12325024, 12522768, 20301447). This variant is present in population databases (rs61753238, gnomAD 0.06%). This premature translational stop signal has been observed in individuals with rhizomelic chondrodysplasia punctata type 1 and Refsum disease (PMID: 11781871, 12325024, 12522768). ClinVar contains an entry for this variant (Variation ID: 7788). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Feb 01, 2003 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 10, 2024 | - - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 17, 2021 | The c.120C>G (p.Y40*) alteration, located in exon 1 (coding exon 1) of the PEX7 gene, consists of a C to G substitution at nucleotide position 120. This changes the amino acid from a tyrosine (Y) to a stop codon at amino acid position 40. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. Based on data from gnomAD, the G allele has an overall frequency of 0.01% (5/55,154) total alleles studied. The highest observed frequency was 0.06% (2/3,332) of Latino alleles. This alteration has been reported compound heterozygous with a second alteration in PEX7 in multiple patients with rhizomelic chondrodysplasia punctata (RCDP) or Refsum disease (Braverman, 2002; van den Brink, 2003). Motley et al. (2002) also reported this alteration in patients with RCDP. Based on the available evidence, this alteration is classified as pathogenic. - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Mar 03, 2022 | - - |
PEX7-related disorder Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 28, 2017 | The PEX7 c.120C>G (p.Tyr40Ter) variant is a stop-gained variant that has been reported in five individuals, including two compound heterozygotes diagnosed with Refsum disease, one compound heterozygote diagnosed with rhizomelic chondrodysplasia punctate (RCDP), and two heterozygotes diagnosed with RCDP in whom a second variant was not identified (Motley et al. 2002; van den Brink et al. 2003; Wood et al. 2014). Control data are unavailable for this variant, which it is not found in the 1000 Genomes Project, the Exome Sequencing Project, or the Exome Aggregation Consortium. In cultured skin fibroblasts from patients carrying the p.Tyr40Ter variant, van den Brink (2003) demonstrated that the variant leads to deficiency of phytanic acid alpha-oxidation, PhyH activity, and plasmalogen synthesis, defective subcellular localization, and an inability to restore thiolase protein transport, as compared to controls. Based on the evidence and the potential impact of stop-gained variants, the p.Tyr40Ter variant is classified as pathogenic for PEX7-related disorders. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
Phytanic acid storage disease;C1859133:Rhizomelic chondrodysplasia punctata type 1;C2749346:Peroxisome biogenesis disorder 9B Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 31, 2018 | - - |
Rhizomelic chondrodysplasia punctata Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Aug 07, 2020 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at